Three-month, open-label, bilateral, parallel group, randomized, daily wear contact lens dispensing study.

Three-month, open-label, bilateral, parallel group, randomized, daily wear contact lens dispensing study comparing the Qualis Silicone Hydrogel Soft Contact Lens for Daily Wear with the currently marketed Acuvue Vita (senofilcon C) Monthly Contact Lens (FDA cleared under K160212). Eligible subjects will be examined for baseline evaluation and lens fitting. Up to fifty (50) subjects will wear the test contact lenses and up to twenty-five (25) subjects will wear the control contact lenses. The subjects will undergo standard ophthalmic evaluation for contact lens wear and will be followed for a period of at least ninety (91) days.

Inclusion Criteria:

• The subject must read, understand, and sign the informed consent form and receive a fully executed copy of the form.
• The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
• The subject must be at least 18 years of age.
• The subject's vertex corrected spherical equivalent distance refraction must be in the range of -1.00 to -6.00 in each eye.
• The subject's refractive cylinder must be ≤ 0.75 Diopters in each eye.
• The subject must have best corrected visual acuity of 20/25 (LogMAR) or better in each eye.
• Subjects should own a wearable pair of spectacles.
• The subject must have normal eyes (i.e., no ocular medications or infections of any type).
• Subjects must be able and willing to wear the study lenses at least 6 hours a day, a minimum of 5 days per week

Exclusion Criteria:

Subjects may not be enrolled into the study if ANY of the following apply:

• Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
• Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, recurrent herpes simplex/zoster, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).
• The use of systemic or ocular medications that would contraindicate contact lens wear.
• Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion by keratometry.
• Any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy, photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK), etc.).
• Any grade 2 or greater slit lamp findings for corneal staining, and any grade 3 or greater slit lamp findings for other abnormalities (e.g., edema, corneal neovascularization, tarsal abnormalities, conjunctival injection) on the ISO 11980 classification scale, any current inflammatory events or events within the last 6 months, or any other ocular abnormality that may contraindicate contact lens wear.
• Any known hypersensitivity or allergic reaction to Biotrue or ClearCare contact lens care solutions
• Any ocular infection, allergy or clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca, ocular hypertension), or ocular conditions (e.g. strabismus), which might interfere with the study.
• Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
• Extended wear, monovision or multi-focal contact lens correction.
• Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.
• Any subject where the randomized lens demonstrates a fit that is deemed inappropriate by the investigator, including, but not limited to, the lens being too flat, too steep, have excessive or inadequate movement, and/or insufficient limbal coverage.
• Employee or relative of employees of sponsor or investigational clinic (e.g., Investigator, Coordinator, Technician)

through study completion, every visit, Day7,Day 14,Day 30, Day 60 and Day 91.

Through study completion, every visit, Day7,Day 14,Day 30, Day 60 and Day 91. by regular investigator assessment. In general, an 'adverse event' refers to any undesirable clinical occurrence in a subject, whether it is considered to be device-related or not.